Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Wesfarmers Centre of Vaccines and Infectious Diseases Deborah Lehmann Research Award

The Wesfarmers Centre has established the Deborah Lehmann Research Award to acknowledge the significant contribution that Clinical Associate Professor Deborah Lehmann AO has made to paediatric infectious disease research.

The Wesfarmers Centre of Vaccines & Infectious Diseases established the Deborah Lehmann Research Award in 2018 to acknowledge the significant contribution that Emeritus Clin A/Prof Deborah Lehmann AO has made to paediatric infectious disease research. 

This award supports the training and development of early- to mid-career researchers (EMCR) or higher degree by research (HDR) students who are nationals from the Pacific Region working in or outside their home countries, researchers from the First Nations of Australia and/or Aotearoa New Zealand, and Pasifika researchers from Aotearoa New Zealand.

Successful applicants will receive up to AU$30,000 in funding towards their research.

Further details on this award and the application process are available in the attached documents. If you have any questions about this award please email WCVID@telethonkids.org.au.

Further information:

Applications close 10 March 2023 at 12:00PM AWST.

2021 Recipient - Paula Tesine

Paula Tesine.jpg

Congratulations to Dr Paula Tesine who is the successful recipient of the Deborah Lehmann Research Award. As the third recipient of the Deborah Lehmann Research Award, Dr Tesine received $30,000 towards her research.

Supported by the Wesfarmers Centre of Vaccines and Infectious Diseases, the Award is designed to provide training and development for early- to mid-career researchers from the Western Pacific, First Nations of Australia and/or Aotearoa New Zealand, and Pasifika researchers.

Dr Tesine’s successful project is titled ‘A window of opportunity? – Safety and feasibility of early postpartum primaquine radical cure of maternal Plasmodium vivax infections to improve maternal and infant outcomes’, and aims to determine how safe and feasible it is to administer primaquine within the first 7 days of life as a cure for Plasmodium vivax malaria in postpartum mothers and their young infants with normal G6PD enzyme activity in Papua New Guinea.

“I live in a country with high rates of malaria infection and transmission, particularly in lowland PNG,” says Dr Tesine. “Diagnosing and treating malaria is a common occurrence. It’s the most common cause for hospital visits with children more commonly presenting with severe malaria and requiring hospital admissions.

“This research will provide insights into primaquine transfer through breastmilk to the young neonate, inform age specific guidelines for use of primaquine in infants, and investigate whether use of primaquine in preventing postpartum vivax malaria will improve infant health outcomes within the first 6 months of life. 

“The dream is to contribute to the production of antimalarial vaccines eventually. But for now, to assist in policy change to improve infant health outcomes in malaria endemic countries.”